Cost Efficiency of National Drug Information Center Services Through Ministry of Health Hotline Calling Center (937) in Saudi Arabia

Yousef Ahmed Alomi$^{1, *}$, Hajar Yousef Almudaiheem$^{2}$

$^{1}$The Former General Manager of General Administration of Pharmaceutical Care Head, National Clinical Pharmacy and Pharmacy Practice, the Past Head and Founder, Research Consult and Pharmacy Consult, Ministry of Health, Riyadh, SAUDI ARABIA.

$^{2}$General Administration of Pharmaceutical Care, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

**Objective:** Since January 2013, the national drug information center (NDIC) has started providing services and since December 2013, it is answering all the public and professional inquiries made through the Ministry of Health (MOH)-Hotline Calling Services (937). Therefore, in this study, we explored the cost avoidance analysis of national drug information inquiries by the hotline services in Saudi Arabia.

**Methods:** We simulated the drug information inquiries related to the adults and children for the duration of 12 months of 2014 through MOH-hotline calling services (937). At least 10 on-call clinical pharmacists and expert trained pharmacists were receiving calls made from public and professionals inquiring about drug information. The data were collected in the drug information data collecting form through manual documentation system of drug information inquiries.

**Results:** The drug information pharmacist implicated that the high-cost avoidance at the public side came from the dose standardization ($30,310 USD (37.5\%)$) of the total cost avoidance followed by the drug administration and adverse drug reaction ($16,532 USD (20.45\%); 9,347.50 USD (11.56\%)$, respectively), which represent more than 50% of the total cost avoidance from the public side. With regard to professional inquiries, the drug information pharmacist implicated that the highest cost avoidance was through inquiries related to drugs in pregnancy, which was around $7,527.50 USD (26\%)$ of the total cost followed by the drug administration, drug−drug interaction and drug identification ($4,792 USD (16.5\%); 4,141.50 USD (14.3\%); and 4,135.50 USD (14.2\%), respectively), which represent more than 50% of the total cost avoidance from the professional side.

**Conclusion:** NDIC was the first in calculating cost avoidance from answering drug information inquiries from professional and public separately in the Middle Eastern countries. It is highly implicated in the drug information services in the healthcare organization in the Kingdom of Saudi Arabia.

**Key words:** Cost, Efficiency, Drug Information Center, Hotline, Ministry of Health, Saudi Arabia.

INTRODUCTION

The quantity and quality of drug information services (DISs) are dramatically changing including the role of the pharmacists.$^{[1-2]}$ Until now, several articles have been published on the DISs and on their impact on other healthcare services and patient care.$^{[3-5]}$ The DISs must validate their importance and maximize their resources to remain a vital component of the healthcare system. In addition, few cost analysis reports have been conducted on the specialty of drug information.$^{[3,5-9]}$ A search on MEDLINE and other databases on
the impact of cost on DISs until 2017 using keywords such as “drug information,” “cost,” “economics” or “pharmacist” revealed only two articles. These articles have focused their research on the cost avoidance and calculation of DISs, economic impact services\[^7\] and cost saving associated with a dedicated DIS in an Academic Medical Center (Jimie N Brown).\[^9\] In previous research conducted in the Hospital of the University of Pennsylvania., drug information responses with Six weeks interval and used the same model, the cost saving during the study interval was 195,000 USD projected to 1-year potential cost savings reached 1.7 million USD. The estimated cost avoidance per call was 342 USD.\[^7\] Another study conducted cost analysis based on the cost of the staff’s salary and the time spent on each question with cost calculation of intervention based on the drug information model and severity rating.\[^9\] Durham Veteran’s Affairs Medical Center in North Carolina had their cost saving calculated for all the interventions. By doing so, they saved a cost of 157,483 USD for 1 year’s research and a total of 186 responses for 1 year. The estimated cost avoidance per call was 846,682 USD. The cost avoidance calculated by total time spent in research by each profession, reached to a total of 2080 hours of work per year. The center had appointed a pharmacist, a family practice physician, a registered nurse, a physician assistant and nurse practitioners with an average hourly wage of 44.59 USD, 91.08 USD, 30.78 USD, 34.82 USD and 42.52 USD, respectively. The inquiries from public accounted for 1% by the healthcare provider; therefore, the cost avoidance cannot be calculated, whereas in Durham Veteran’s Affairs Medical Center in North Carolina, the inquiries accounted for 49% based on the estimation of hourly work done per year for each profession. In the Hospital of the University of Pennsylvania, it was 17.7% which by used the same model of cost saving.\[^9\] To the best of our knowledge, there are no studies performed to investigate the economic impact of DISs in Saudi Arabia, Gulf, or Middle Eastern countries. Therefore, in this study, we aimed to explore the cost avoidance of national drug information center at Ministry of Health in the Kingdom of Saudi Arabia.

**METHODS**

We simulated the drug information inquiries for all 12 months of 2014 related to adults and children through MOH-hotline calling services (937). There were 10 on-call clinical pharmacists and expert trained pharmacists to receive calls from the public and professionals inquiring about drug information. The data were collected in the drug information data collecting form through electronic documentation system of drug information inquiries. The cost avoidance calculations were performed through Survey Monkey system. All documented calls received by 937 hotline services from January 2013 to December 2014 were analyzed and the pharmacist used drug information inquiries to calculate cost avoidance per question based on the American model.\[^7\] Then, the total number of calls, excluding all poisoning calls, were included for the calculation. Any calls that were not documented were also excluded in this study.

**RESULTS**

A total of 1479 calls were received during the 12-month study period. Several drug information calls (976 (67.13%)) and poisoning calls (17 (1%)) were answered; there were 421 (28.46%) missed calls and 65 (4.49%) closed calls. Of all the responded calls, only 264 (27%) calls including a total of 300 inquiries where documented. The estimated total cost with complete documentation was found to be 405,801 USD per year. The average cost avoidance per call was found to be 415.78 USD and total cost avoidance was found to be 109,768 USD with incomplete documentation. The cost avoidance of answering public inquiries was found to be 80,806.5 USD and the cost avoidance due to professional inquiries were found to be 28,961.5 USD. Drug information pharmacist implicated that the highest cost avoidance on the public side was from dose standardization (30,310 USD (37.5%) of the total cost avoidance) followed by drug administration and adverse drug reaction (16,532 USD (20.45%) and 9,347.5 USD, respectively. The inquiries accounted for 49% based on the estimation of hourly work done per year for each profession. In the Hospital of the University of Pennsylvania, it was 17.7% which by used the same model of cost saving.\[^9\] To the best of our knowledge, there are no studies performed to investigate the economic impact of DISs in Saudi Arabia, Gulf, or Middle Eastern countries. Therefore, in this study, we aimed to explore the cost avoidance of national drug information center at Ministry of Health in the Kingdom of Saudi Arabia.

| Inquiry classification type of inquiries by public | Cost avoidance (USD) |
|--------------------------------------------------|----------------------|
| Dose standardization                              | 30,310               |
| Drug Administration                               | 16,532               |
| ADR                                              | 9,347.5              |
| Drug in pregnancy                                 | 8,298.5              |
| Drug availability/ formulaary                     | 6,810                |
| Others                                           | 3,972.5              |
| Compatibility                                     | 2,598                |
| Drug Identification                               | 1,550.5              |
| Drug-drug interaction                             | 838                  |
| Drug-Nutrition interaction                        | 291.5                |
| Drugs in breast feeding                           | 129                  |
| Pharmacokinetic                                  | 64.50                |
| Compounding                                       | 64.50                |
| Total                                            | 80,806.5             |

Alomi and Almudaiheem, et al.: Cost Efficiency of National Drug Information Center Services in Saudi Arabia
Table 2: Percentage of inquiry classification for public and professional side.

| Inquiry classification | Public and Professional Cost Avoidance % | Public Cost Avoidance % | Professional Cost Avoidance % |
|------------------------|------------------------------------------|-------------------------|-------------------------------|
| Dose standardization   | 27                                       | 27.77                   | 25.83                         |
| Drug Administration    | 15.33                                    | 16.11                   | 14.16                         |
| Drug in pregnancy      | 7.66                                     | 12.7                    | 8.33                          |
| ADR                    | 11.66                                    | 9.47                    | 15                            |
| Drug availability/ formulary | 9.66                    | 9.4                     | 5                             |
| Drug Identification    | 10                                       | 7.22                    | 9.16                          |
| Drug-drug interaction  | 7.33                                     | 6.66                    | 10.83                         |
| Others                 | 6                                        | 5                       | 5                             |
| Compatibility          | 1                                        | 1.66                    | 1.66                          |
| Drugs in breast feeding | 2                                      | 1.11                    | 2.5                           |
| Compounding            | 1.33                                     | 0.55                    | 2.5                           |
| Drug-Nutrition interaction | 0.66                                | 0.55                    | 0                             |
| Pharmacokinetic        | 0.33                                     | 0.55                    | 0                             |
| Total                  | 100                                      | 100                     | 100                           |

Table 3: Cost avoidance of healthcare professional inquiries.

| Type of inquiries by professional | Cost avoidance (USD) |
|-----------------------------------|----------------------|
| Drug in pregnancy                 | 7,527.50             |
| Drug Administration               | 4,792                |
| Drug-drug interaction             | 4,141.50             |
| Drug Identification               | 4,135.50             |
| Dose standardization              | 3,885                |
| ADR                               | 3,445.50             |
| Drugs in breast feeding           | 356                  |
| Compounding                       | 291.5                |
| Others                            | 258                  |
| Compatibility                     | 64.50                |
| Drug availability/ formulary      | 64.50                |
| Drug-Nutrition interaction        | 0                    |
| Pharmacokinetic                   | 0                    |
| Total                             | 28,961.5             |

USD (11.56%), respectively) which represent more than 50% of the total cost avoidance from the public side (Tables 1 and 2). However, with respect to the professional inquiries, the drug information pharmacist implicated that the highest cost avoidance was through inquiries related to drugs used in pregnancy (7,527.50 USD (26%) of the total cost), followed by the drug administration, drug–drug interaction and drug identification (4,792 USD (16.5%); 4,141.50 USD (14.3%); and 4,135.50 USD (14.2%), respectively), which represent more than 50% of the total cost avoidance from the professional side (Table 3).

The general administration of pharmaceutical care established the national drug information center in early 2013.[1] It provided services to the professionals and public regarding medications. In late 2013, the national drug information center participated with hotline call (937) to answer the professional and public drug information inquiries until this time. During the first year, all pharmacists documented the calls received in electronic format through Survey Monkey system through internet. All required documentation, in addition to the documentation of cost avoidance from answering the inquiries, was based on the guidelines of the American Society of Health-System Pharmacists.[2] The author analyzed all the related results. During the 12-month period, the total cost was found to be high with few drug information inquiries, which is related to the high impact of prevention of drug-related problems. The average cost avoidance per call was found to be high, which is because of the importance of questions and weak background knowledge in the professional and public side. The estimated cost avoidance in this study was found to be almost similar to those reported by Kinky et al., but it differs from other investigations due to difference in the method of cost calculation.[5,7,9] The cost avoidance was found to be more from the public side than that of healthcare professionals’ side, which is related to the number and quality of drug information inquiries. The highest cost avoidance from the drug information inquiries from the public side was from drug standardization, drug administration and adverse drug reaction and represented almost half of the total cost avoidance. This reflects the weak background and knowledge regarding drugs at the public side. Moreover, the patient medications counseling was not widely implemented at the Ministry.

DISCUSSION
of Health hospitals. The highest cost avoidance from
the professional side was pregnancy and lactation, drug
administration and drug–drug interaction, in addition
to drug identification. Therefore, that is tied no available
freely drug information resources with them or the
physician not familiar with drug information resources
with additional demanding of knowledge of those type
drug information inquiries. Our results could not be
compared with those from the literature due to lack of
information. A previous study focused their research
on the potential of national drug information centers
to answer inquiries from the healthcare professional
and public side. The drug information services were in
great demand for both national or regional hospital.
Furthermore, educational sessions to train the
professionals or the public is necessary to avoid any
additional cost, including patients counseling program,
at all healthcare organizations at the Ministry of Health
in the Kingdom of Saudi Arabia.

CONCLUSION

To the best of our knowledge, this is the first article to
address cost avoidance classified by drug information
inquiry for both public and healthcare providers; this
shows the importance of having drug information in
each hospital and the economic impact in just serving
one task of DISs. This also sheds some light on how
necessary and crucial is the documentation for each
function as it does not only justify the services to get
more support but also to monitor and improve it.

ACKNOWLEDGMENT

None.

CONFLICT OF INTEREST

None.

ABBREVIATIONS

NDIC: National Drug Information Center; DISs: Drug
Information Services; KSA: Kingdom of Saudi Arabia;
MOH: Ministry of Health; ASHP: American Society of
Health-System Pharmacists.

ORCID ID

Yousef Ahmed Alomi https://orcid.org/0000-0003-
1381-628X

REFERENCES

1. Alomi YA. National Drug Information Center Program at Ministry of Health
in Saudi Arabia. Adv Pharmacoepidemiol Drug Saf. 2016;5(1):1-2.
2. Alomi YA, Mudaiheem H A. National Drug Information Center Services
through Ministry of Health Hotline Calling Center (937) in Saudi Arabia.
Adv Pharmacoepidemiol Drug Saf. 2016;5(1).
3. Skoutakis VA, Wojciechowski NJ, Carter CA, Hayes JM, Hudson BL,
Martin JA. Drug Information Center network: need, effectiveness and cost
justification. Drug Intell Clin Pharm. 1987;21(1):49-56.
4. World P, Central P. A systematic review of the clinical and economic
impact of drug information services on patient outcome. Pharm World
Sci. 2002;24(4):132-8.
5. Ponampalam R, Loh CS. Cost benefits of the Drug and Poison Information
Centre in preventing unnecessary hospitalisation: The Singapore
experience. Hong Kong J Emerg Med. 2010;17(1):45-53.
6. Lyrvall H, Nordin C, Jonsson E, Alvan G, Öhman B. Potential savings
of consulting a drug information center. Annals of Pharmacotherapy.
1993;27(12):1540.
7. Kinky DE, Erush SC, Laskin MS, Gibson GA. Economic impact of a drug
information service. Ann Pharmacother. 1999;33(1):11-6.
8. Marrone CM, Heck AM. Impact of a Drug Information Service: Practitioner
Hours Saved. Hosp Pharm. 2000;35(10):1065-70.
9. Brown JN. Cost Savings Associated With a Dedicated Drug Information
Service in an Academic Medical Center. Hosp Pharm. 201;46(9):680-4.

Cite this article as: Alomi YA, Almudaiheem HY. Cost Efficiency of National Drug Information Center Services Through
Ministry of Health Hotline Calling Center (937) in Saudi Arabia. Int J Pharmacol. Clin. Sci. 2019;8(1):17-20.